Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Thorac Dis ; 15(12): 6889-6897, 2023 Dec 30.
Article in English | MEDLINE | ID: mdl-38249895

ABSTRACT

Background: The detection of pulmonary nodules significantly impacts the lives and mental health of patients. Although the 2020 National Comprehensive Cancer Network (NCCN) guidelines recommend scheduled surveillance for nodules ≤8 mm, patients often opt to have their nodules surgically removed. Methods: A cross-sectional questionnaire was administered to patients with small pulmonary nodules who presented to a local grade 3 hospital with small pulmonary nodules and decided to receive surgery versus prescribed monitoring. The questionnaire included four aspects: (I) patient characteristics; (II) nodule-specific knowledge; (III) doctor-patient communication; and (IV) nodular-specific distress. Nodular-specific distress was measured by the Impact of Event Scale-Revised (IES-R). Results: A total of 234 (69%) patients responded to the survey and were included in the final analysis. Poor performance in activities of daily living (ADLs), the presence of solid nodules, multifocal disease, and a family history of lung cancer were significantly associated with reported anxiety. Most notably, facilitating patient choice for surgery was the computed tomography (CT) scan results, with reference to lung nodule size and number of nodules, where concerns related to lung nodule, cancer risk, and fear of surgery or death had a significant psychological impact on patients. Conclusions: In this cohort of patients who elected to have their small pulmonary nodules surgically removed, we identified key factors underlying their anxiety toward guideline recommended surveillance. Our findings will be useful for clinicians when discussing treatment options with their patients.

2.
Curr Pharm Des ; 28(21): 1695-1702, 2022.
Article in English | MEDLINE | ID: mdl-35440302

ABSTRACT

Vitamin D is an important immune-modulator with anti-inflammatory properties. While this prohormone has been studied extensively in the prevention and treatment of COVID-19, findings have been inconsistent regarding its overall benefit in patients hospitalized with COVID-19. Most studies to date have been observational in nature, not accounting for the use of corticosteroids. Furthermore, the few randomized clinical trials designed to examine the effect of vitamin D supplementation on COVID-19 outcomes have been relatively small and thus insufficiently powered to assure a balance of corticosteroid use between study arms. The current perspective addresses the interaction of vitamin D and corticosteroids as a potential explanation for the divergent results reported in the literature. Future research on vitamin D and COVID-19 will benefit by considering this interaction, especially among hospitalized patients requiring oxygen and mechanical ventilation.


Subject(s)
COVID-19 Drug Treatment , Adrenal Cortex Hormones/therapeutic use , Humans , SARS-CoV-2 , Vitamin D/therapeutic use , Vitamins
3.
Shock ; 42(3): 185-91, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24727868

ABSTRACT

Previous studies have shown conflicting evidence regarding the impact of inappropriate, initial antibiotic therapy. The purpose of this study was to evaluate the impact of inappropriate empiric antimicrobial therapy for the treatment of infection among surgical patients. We hypothesized that inappropriate empiric antimicrobial therapy would predict increased mortality risk compared with appropriate therapy. This was a retrospective analysis of a prospectively maintained database of all surgical patients admitted to a tertiary care center from 1996 to 2007 and treated for sepsis. "Appropriate" empiric antibiotic treatment was determined by sensitivity testing. Demographics and comorbidities, infection sites, infection organisms, and outcomes were compared between inappropriately and appropriately treated groups. Multivariable log-binomial regression was performed. There were 2,855 patients (7,158 infectious episodes) identified by culture analysis as either appropriately or inappropriately treated. Three hundred seventeen (15%) inappropriately treated infectious episodes resulted in death compared with 718 (14%) of the appropriately treated infectious episodes. After adjusting for statistically significant variables, inappropriately treated episodes of infection were not found to be associated with an increased risk for mortality compared with appropriately treated episodes of infection (relative risk, 1.0; 95% confidence interval, 0.99 - 1.02; P = 0.36). Our study observed no difference in mortality between appropriately and inappropriately treated infections within a surgical population.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Medication Errors , Sepsis/drug therapy , Surgical Wound Infection/drug therapy , Adult , Aged , Comorbidity , Female , Guideline Adherence , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Practice Guidelines as Topic , Practice Patterns, Physicians' , Predictive Value of Tests , Retrospective Studies , Risk Assessment , Risk Factors , Sepsis/diagnosis , Sepsis/microbiology , Sepsis/mortality , Surgical Wound Infection/diagnosis , Surgical Wound Infection/microbiology , Surgical Wound Infection/mortality , Tertiary Care Centers , Treatment Outcome , Virginia
4.
Int J Environ Res Public Health ; 11(2): 2328-45, 2014 Feb 21.
Article in English | MEDLINE | ID: mdl-24566057

ABSTRACT

Bitter Melon (Momordica charantia) is a widely used traditional remedy for hyperglycemia. While the medicinal properties of this plant have been studied extensively using in vitro and animal models, the clinical efficacy and safety in humans is largely unknown. This review discusses the benefits and limitations of bitter melon supplementation in the context of epidemic levels of insulin resistance and pre-diabetes throughout the world.


Subject(s)
Insulin Resistance , Momordica charantia , Phytotherapy , Plant Preparations/therapeutic use , Prediabetic State/drug therapy , Animals , Blood Glucose/drug effects , Humans , Plant Preparations/pharmacology , Randomized Controlled Trials as Topic
5.
Nutr J ; 10: 78, 2011 Jul 28.
Article in English | MEDLINE | ID: mdl-21794176

ABSTRACT

BACKGROUND: Although beneficial to health, dietary phytonutrients are bitter, acid and/or astringent in taste and therefore reduce consumer choice and acceptance during food selection. Momordica charantia, commonly known as bitter melon has been traditionally used in Ayurvedic and Chinese medicine to treat diabetes and its complications. The aim of this study was to develop bitter melon-containing recipes and test their palatability and acceptability in healthy individuals for future clinical studies. METHODS: A cross-sectional sensory evaluation of bitter melon-containing ethnic recipes was conducted among 50 healthy individuals. The primary endpoints assessed in this analysis were current consumption information and future intentions to consume bitter melon, before and after provision of attribute- and health-specific information. A convenience sample of 50, self-reported non-diabetic adults were recruited from the University of Hawaii. Sensory evaluations were compared using two-way ANOVA, while differences in stage of change (SOC) before and after receiving health information were analyzed by Chi-square (χ2) analyses. RESULTS: Our studies indicate that tomato-based recipes were acceptable to most of the participants and readily acceptable, as compared with recipes containing spices such as curry powder. Health information did not have a significant effect on willingness to consume bitter melon, but positively affected the classification of SOC. CONCLUSIONS: This study suggests that incorporating bitter foods in commonly consumed food dishes can mask bitter taste of bitter melon. Furthermore, providing positive health information can elicit a change in the intent to consume bitter melon-containing dishes despite mixed palatability results.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/therapeutic use , Momordica charantia , Phytotherapy , Plant Extracts/therapeutic use , Adolescent , Adult , Aged , Blood Glucose/analysis , Cooking/methods , Cross-Sectional Studies , Diet , Female , Humans , Male , Middle Aged , Pilot Projects , Surveys and Questionnaires , Taste , Vegetables/chemistry , Young Adult
6.
Toxicol Sci ; 97(1): 214-21, 2007 May.
Article in English | MEDLINE | ID: mdl-17329236

ABSTRACT

Kava-containing products remain popular in the United States and continue to be sold in health food stores and ethnic markets regardless of the fact that it was banned in Western countries such as Germany, France, Switzerland, Australia, and Canada, following reports of alleged hepatotoxicity. It is therefore critical to establish efficacy and verify adverse effects and/or herb-drug interactions for kava-kava (Piper methysticum). We have previously demonstrated that kava alkaloid, pipermethystine (PM), abundant in leaves and stem peelings, induces mitochondrial toxicity in human hepatoma cells, HepG2, as compared with the bioactive components, kavalactones (KL), abundant in the rhizome. The current study compared short-term toxic effects of PM in Fischer-344 (F-344) rats to acetone-water extracts of kava rhizome (KRE). Treatment of F-344 rats with PM (10 mg/kg) and KRE (100 mg/kg) for 2 weeks failed to elicit any significant changes in liver function tests or cause severe hepatic toxicity as measured by lipid peroxidation and apoptosis markers such as malondialdehyde, Bax, and Bcl-2. However, PM-treated rats demonstrated a significant increase in hepatic glutathione, cytosolic superoxide dismutase (Cu/ZnSOD), tumor necrosis factor alpha mRNA expression, and cytochrome P450 (CYP) 2E1 and 1A2, suggesting adaptation to oxidative stress and possible drug-drug interactions.


Subject(s)
Alkaloids/toxicity , Cytochrome P-450 Enzyme System/biosynthesis , Kava , Lactones/toxicity , Liver/drug effects , Liver/metabolism , Oxidative Stress/drug effects , Pyridones/toxicity , Alkaloids/isolation & purification , Animals , Cytochrome P-450 CYP1A2/biosynthesis , Cytochrome P-450 CYP2D6/biosynthesis , Cytochrome P-450 CYP2E1/biosynthesis , Cytochromes , Enzyme Induction/drug effects , Glutathione/genetics , Glutathione/metabolism , Lactones/isolation & purification , Liver/enzymology , Male , Mitochondria, Liver/drug effects , Mitochondria, Liver/metabolism , Plant Extracts/chemistry , Plant Extracts/toxicity , Plant Leaves , Pyridones/isolation & purification , RNA, Messenger/metabolism , Rats , Rats, Inbred F344 , Reactive Oxygen Species/metabolism , Rhizome , Superoxide Dismutase/genetics , Superoxide Dismutase/metabolism , Time Factors , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism , Up-Regulation
SELECTION OF CITATIONS
SEARCH DETAIL